Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in HPB-ALL cell line  by Russo, Maria et al.
Quercetin and anti-CD95(Fas/Apo1) enhance apoptosis in
HPB-ALL cell line
Maria Russo, Rosanna Palumbo, Idolo Tedesco, Giuseppe Mazzarella, Paola Russo,
Giuseppe Iacomino, Gian Luigi Russo*
Institute of Food Science and Technology, CNR, Via Roma 52 A/C, 83100 Avellino, Italy
Received 1 October 1999; received in revised form 27 October 1999
Edited by Jesus Avila
Abstract Several malignant cell lines are resistant to CD95-
(Apo1/Fas)-mediated apoptosis, even when the CD95 receptor is
highly expressed. Sensitivity to CD95-induced apoptosis can be
restored using different molecules. In this study, we showed that
quercetin, a naturally occurring flavonoid, in association with the
agonistic anti-CD95 monoclonal antibody, increases DNA
fragmentation and caspase-3 activity in HPB-ALL cells. These
cells have been selected for their known resistance to CD95-
induced apoptosis. At molecular level, quercetin lowers the level
of intracellular reactive oxygen species, reduces mitochondrial
transmembrane potential, thereby leaving the expression of
CD95 receptor unchanged.
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1. Introduction
A great deal of evidence indicates that cancer is the result of
a reciprocal interaction between genetic susceptibility and en-
vironmental factors. In this respect, dietary habit plays a fun-
damental role. Following the recent publication from the
American Institute for Cancer Research [1], a ‘correct’ diet
could decrease the cancer rate by as much as 20%. For certain
cancers, the correlation is even more dramatic. Recent studies
have focused on the activity of non-nutritional compounds,
present in the diet, that can prevent the occurrence of degen-
erative diseases such as cancer. This class of molecules, gen-
erally known as chemopreventers [2] includes some vitamins
and food polyphenols. Flavonoids are polyphenolic antioxi-
dants naturally present in vegetables, fruits, and beverages
such as tea and wine [3]. A large number of epidemiological
and molecular studies suggest that a daily intake of £avonoids
could reduce the incidence of several types of cancers [4,5].
Quercetin (3,3P,4P,5,7-pentahydroxy£avone) is the major di-
etary £avonoid particularly abundant in fruit and vegetables
[3], with a daily intake of 16 mg in European countries [6].
Some food, such as wine and tea, may contain a concentra-
tion of quercetin up to 150 WM [7]. This molecule has been
reported to inhibit the growth of various cell lines derived
from human cancers [8,9] ; it blocks the cell division cycle at
di¡erent points depending on the cell type and tumor origin:
at G2/M transition [8^10], or G1/S [11,12]. In addition, quer-
cetin exerts a well documented pro-apoptotic activity [9,13^15]
that generally follows cell cycle block. This suggests that the
failure of malignant cells to pass quercetin-dependent cell
cycle arrest can trigger apoptosis. However, despite the large
number of data on the antiproliferative and pro-apoptotic
e¡ects of quercetin, its mechanism of action is still unknown.
Quercetin seems to modulate cellular neoplastic phenotype by
down-regulating the expression of mutated H-ras and p53 [8],
c-myc and K-ras [16], or up-regulating p21WAF1=CIP1 [14]. Al-
ternatively, quercetin activity might be related to its ability to
inhibit various protein kinase and serine/threonine protein
kinases [17^19]. Despite these data, several controversial re-
sults have been published on the real bene¢cial e¡ect of quer-
cetin [2,20,21]. Concerns have been expressed on the presence
of quercetin and other £avonoids in food as potential geno-
toxic hazard since they can induce p53-mediated apoptosis in
non-tumor cells [10]. In normal cells, quercetin inhibits apop-
tosis via suppression of the tyrosine kinase/c-Jun/AP-1 path-
way triggered by oxidative stress [22].
CD95 and its ligand, CD95-L, play a key role in several
types of physiological apoptosis [23,24]. CD95-mediated
apoptosis can be triggered by the natural ligand of the recep-
tor, CD95-L expressed on several cell types included killer
cells, or by agonistic antibodies such as anti-CD95 [23,25].
The best understood signal transduction pathway of CD95-
mediated apoptosis involves activation of FADD and casp-
ase-8 that triggers the protease cascade leading to the acti-
vation of downstream e¡ector caspases such as caspase-3 -6
and -7 depending on cell type origin [26,27]. Activation of
CD95 pathway also induces a mitochondria-dependent apop-
totic event [28^30]. However, di¡erent cell types utilize either
of the two CD95 signaling pathways depending on the speci¢c
type [26,27].
In order to study the e¡ect of quercetin in CD95-induced
apoptosis, we chose HPB-ALL cell line derived from a human
tymoma [31]. These cells are characterized by unusual resist-
ance to apoptosis induced in vitro, and are derived from a
tumor type with alteration in the CD95 pathway of signal
transduction [25]. The majority of ALL (acute lymphoblastic
leukemia) are resistant to CD95-triggered apoptosis, resem-
bling the relative resistance of most human thymocytes,
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although they express signi¢cant (or high) levels of CD95.
Explanations for this apparent contradiction might include
defects in the receptor, or ligand, or other molecules involved
in the apoptotic signaling [25].
In this report, we showed that quercetin is able to sensitize
malignant cells normally resistant to CD95-mediated apopto-
sis. Our results suggest that the molecule sustains this role by
acting at several levels on the signal transduction pathway
triggering CD95-mediated apoptosis.
2. Materials and methods
2.1. Cell culture
Human tymoma-derived HPB-ALL cells [31] were cultured in
RPMI medium (Gibco-BRL) supplemented with 10% fetal bovine
serum, 1% penicillin/streptomycin, 1% L-glutamine in a 5% CO2 in-
cubator at 37‡C. Cells were commonly grown in 100 mm Petri dishes
and the medium was changed every 48 h.
2.2. Detection of viability and cell death
To assay the e¡ect of quercetin on cell growth, viability was deter-
mined by trypan blue exclusion. Percentage of viable cells was esti-
mated after counting 100 cells for each sample. The cytotoxicity of
anti-CD95, quercetin or both on HPB-ALL was assayed by neutral
red viability test uptake. Cells were seeded (2^3U105/well) in a 12
multiwell plate and incubated with medium containing 0.1% DMSO
(control), 50 ng/ml anti-CD95, 50 WM quercetin dissolved in 0.1%
DMSO for 12 h. Subsequently, neutral red (0.066% v/v in the culture
medium) was added, and cells incubated for 3 h. To estimate the
incorporation of dye, cells were incubated for 15 min with a lysis
bu¡er (50 mM Tris-HCl pH 7.4; 150 mM NaCl; 5 mM dithiothreitol,
and 1% Triton X-100) containing 1% acetic acid and 50% ethanol.
Finally, absorbance was measured spectrophotometrically at 540 nm.
Apoptosis in HPB-ALL cells was determined using an in situ cell
death detection kit (Boehringer Mannheim). Fixed cells with £uores-
cein-labelled DNA strand breaks were subsequently stained with pro-
pidium iodide and observed at confocal microscopy (Leica TCS SP).
Percentage of apoptotic cells was estimated after counting at least 500
cells for each sample.
2.3. Caspase-3 activity
To study the early events of apoptosis in HPB-ALL, we assayed
caspase-3 (CPP32/caspase-3/Apopaine) protease activity using a com-
mercially available Apopain assay kit (BioRad). Brie£y, cells were
incubated with medium containing 0.1% DMSO, 50 ng/ml anti-
CD95, 50 WM of quercetin, or both for 6 h, and samples were assayed
at 37‡C for 30 min in the presence of the speci¢c conjugated substrate
Z-DEVD-AFC (carbobenzoxy-Asp-Glu-Val-Asp-7-amino-4-tri£uoro-
methyl coumarin), according to the manufacturer’s instructions.
Upon proteolytic cleavage of the substrate by caspase-3, the free £u-
orochrome AFC was detected by a spectro£uorimeter (Perkin Elmer
LS 50B) with excitation and emission setting at 395 nm and 540 nm,
respectively. To quantify enzymatic activity, we made a standard
curve of AFC. Caspase-3 speci¢c activity in each sample was calcu-
lated as Wmoles of AFC produced/min/Wg protein at 37‡C at saturat-
ing substrate concentrations (49 WM).
2.4. Immunoblotting
For Western blotting analysis, cells (4^5U106 for each sample) were
lysed in 100 Wl lysis bu¡er (50 mM Tris pH 7.6; 150 mM NaCl; 5 mM
EDTA; 1% NP-40; 0.5 mM dithiothreitol; 10% glycerol containing
100 Wg/ml phenylmethylsulfonyl, and a cocktail of protease inhibitors
(complete’ by Boehringer). Proteins in the cell lysates (20 Wg/lane)
were separated by 15% SDS-PAGE before blotting onto PVDF (poly-
vinylidene £uoride, Millipore) membrane. The membrane blot was
incubated with anti-CD95 antibody (CH11, Immunotech, Marseille,
France) diluted 1:500. Following incubation with a horseradish per-
oxidase-linked secondary antibody, CD95 was revealed using a chem-
iluminescence detection kit (ECL-Plus, Amersham). For quantitative
analysis of protein expression, the same membrane was stripped and
probed with anti-K-tubulin monoclonal antibody (Sigma). Densito-
metric analysis of the bands was performed using GEL DOC 2000
system (BioRad).
2.5. Cyto£uorimetric analysis of v8m
Variations of the mitochondrial transmembrane potential (v8m)
during cellular apoptosis were studied using the cationic lipophilic
dye 3,3P-dihexyloxacarbocyanine iodide (DiOC6) [32] (Molecular
Probe). This cyanine dye accumulates in the mitochondrial matrix
under the in£uence of v8m. HPB-ALL cells were incubated with
di¡erent reagents for 4.5 h, and treated with 100 Wl of 0.1 WM DiOC6
for 30 min. DiOC6 membrane potential related £uorescence was re-
corded using £ow cytometry (Becton Dickinson).
2.6. Reactive oxygen species (ROS) measurement
To detect intracellular ROS production in HPB-ALL cells, we used
a spectro£uorimetric method [33]. ROS production was assayed using
2P,7P-dichloro£uorescin diacetate (DCFDA, Molecular Probe), a non-
£uorescent compound that freely permeates cells. Cells (1.5U106/ml)
were incubated with 50 WM of quercetin at di¡erent times, and in-
cubated with 10 WM DCFDA for 30 min.
3. Results
3.1. E¡ect of quercetin on cell growth
In order to evaluate the capability of quercetin to induce
apoptosis in HPB-ALL cell line, we ¢rst tested the e¡ects of
the molecule on cell growth. Fig. 1 shows that at a concen-
tration up to 200 WM, quercetin was not toxic until 12 h of
treatment compared to untreated cells. However, after a pro-
longed exposure (24 h), HPB-ALL presented a dose-depend-
ent decrease in cellular viability as measured by trypan blue
exclusion assay, indicating a general cytotoxic e¡ect of quer-
cetin. Based on these data, in our experiments we used a
concentration of 50 WM quercetin, and we limited our obser-
vation at time points shorter than 12 h to avoid the possible
toxic e¡ects of the molecule.
3.2. Sensitivity to CD95-mediated apoptosis in HPB-ALL
To determine sensitivity of HPB-ALL to CD95-mediated
apoptosis, we measured their dose dependence response to
the agonistic antibody CH11 able to induce apoptotic cell
death in di¡erent systems [34,35]. In HPB-ALL, anti-CD95
decreased 20% cell viability starting from a concentration of
50 ng/ml, one which falls within the range of that active in
other systems [34,35] (Fig. 2). The maximal e¡ect of anti-
CD95-induced apoptosis was observed at a concentration
10-fold higher (40% decrease in cellular viability compared
to untreated and IgM treated cells). Therefore, HPB-ALL
cells were sensitive to 50 ng/ml anti-CD95-induced apoptosis,
while saturation of CD95 receptor was detectable starting
Fig. 1. E¡ect of quercetin on cell growth of HPB-ALL cell line.
Cells were plated at a density of 5.0U105, and treated with the indi-
cated concentration of quercetin. After trypan blue staining, the
number of viable cells was determined at di¡erent time intervals
after the onset of the treatment. Results represent the average of
three experiments. Bars represent standard error.
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from a concentration of 500 ng/ml of antibody. In the light of
the data reported in Fig. 2, we used in our experiments a
concentration of anti-CD95 of 50 ng/ml. This value corre-
sponded to a decrease in cell viability related to the pro-apop-
totic activity of the antibody.
3.3. E¡ect of quercetin and anti-CD95 antibody on
CD95-induced apoptosis
To investigate the e¡ect of quercetin on CD95-induced
apoptosis, we incubated HPB-ALL cells with 50 ng/ml anti-
CD95 antibody in the presence of 50 WM quercetin for 12 h,
and then we analyzed apoptotic cells as described in Section 2.
Untreated HPB-ALL cells (Fig. 3A) and those treated solely
with quercetin (not shown) displayed a number of apoptotic
elements lower than 6% as determined by TUNEL (TdT-
mediated dUTP nick end labelling) assay (Fig. 3C). Incuba-
tion with CH11 increased the number of apoptotic elements to
about 12% (Fig. 3C). When quercetin and CH11 were added
Fig. 2. Sensitivity of HPB-ALL cells to CD95-mediated apoptosis.
HPB-ALL were incubated at the density reported in Fig. 1 for 12 h
with the indicated concentration of anti-CD95 antibody. After incu-
bation, cells were harvested and cell viability determined by neutral
red assay. IgM (1000 ng/ml) indicates a control antiserum. The data
are representatives of three independent experiments in duplicate.
Bars represent standard error.
Fig. 3. Associative e¡ect of quercetin and anti-CD95 in CD95-mediated apoptosis. HPB-ALL cells (1U106) were incubated for 12 h in the
presence of 50 WM quercetin and 50 ng/ml anti-CD95 monoclonal antibody (CH11). DNA fragmentation was detected microscopically by TU-
NEL test (A, B). The average of two experiments is shown, and at least 500 cells were counted per experiment (C). In panel D, cell viability
measured by trypan blue exclusion is shown. The data are representatives of two independent experiments in duplicate. Bars represent standard
error. In panel C, ANOVA: P6 0.001. In panel D, ANOVA: P6 0.01. *P6 0.05 vs. [untreated] and [anti-CD95+quercetin treated] cells.
2P6 0.05 vs. [untreated] and [anti-CD95 treated] cells.
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together, apoptosis increased up to 22% (Fig. 3B and C). To
con¢rm the associative e¡ect of quercetin and anti-CD95 in
CD95-induced apoptosis, we measured changes in cell viabil-
ity using trypan blue assay. Fig. 3D shows a decrease in cell
viability of 50% when quercetin and anti-CD95 were used
together compared to the 20% determined by anti-CD95 anti-
body.
3.4. E¡ect of quercetin and anti-CD95 on caspase-3 activity
To characterize the apoptotic pathway triggered by querce-
tin in association with anti-CD95 antibody, we measured a
di¡erent marker of apoptotic induction downstream to CD95,
such as caspase-3 activity. HPB-ALL cells showed a clear
increase in caspase-3 activity after treatment with anti-CD95
antibody (Fig. 4). However, this enzymatic activity was sig-
ni¢cantly enhanced when quercetin was coupled to CH11; in
fact, caspase-3 activity increased 1.5-fold with respect to
CH11 treated cells (Fig. 4).
3.5. E¡ect of quercetin on CD95 expression
In order to investigate the possible mechanism(s) responsi-
ble for the observed associative e¡ect of quercetin and anti-
CD95 in mediating apoptosis, we hypothesized that a change
Fig. 4. E¡ect of quercetin on caspase-3 protease activity of anti-
CD95 treated cells. HPB-ALL cells were lysated and caspase-3 enzy-
matic activity measures as described in the manufacturer’s protocol.
Each experiment was performed starting from 4^5U106 cells. The
amount of cell lysate tested in each assay was approximately 5^10
Wg. The data are representatives of three independent experiments.
Bars represent standard error. ANOVA: P6 0.001.
Fig. 5. CD95 expression following quercetin treatment of HPB-ALL
cells. Immunoblotting analysis of CD9 receptor performed using
anti-CD95 monoclonal CH11. Each lane contains 20 Wg of cell ex-
tract. After the ¢rst immunoblotting the PVDF membrane was
stripped and re-probed with a control antibody anti-K-tubulin.
Fig. 6. Changes in v8m in HPB-ALL due to quercetin treatment. HPB-ALL cells (1U106) were incubated with 50 WM quercetin (A), 50 WM
quercetin plus 50 ng/ml anti-CD95 (B), and 50 ng/ml anti-CD95 (C). All the experiments were performed for 4.5 h. Drop in v8m was meas-
ured by loading cells with the £uorochrome DiOC6 and subsequent £ow cytometric analysis.
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in the expression of CD95 receptor due to quercetin treatment
could explain the increased sensitivity of cells to anti-CD95.
Flow cytometric analysis of CD95 expression in HPB-ALL
indicated that quercetin treatment for several hours (1^4)
did not induce any signi¢cant change in the expression of
the receptor (data not reported). To further con¢rm these
data, we performed an immunoblotting analysis of CD95 re-
ceptor after prolonged exposure to quercetin (6^12 h) using
CH11 antibody. Fig. 5 clearly shows no change in CD95 ex-
pression.
3.6. E¡ect of quercetin on mitochondrial transmembrane
potential
The loss of mitochondrial transmembrane potential (v8m)
associated with CD95-mediated apoptosis, has been described
in di¡erent cell lines [27,36]. Therefore, we hypothesize that
quercetin could enhance CD95-mediated apoptosis by acting
at the level of v8m. To verify whether this mechanism was
active, we loaded HPB-ALL cells treated with quercetin with
the £uorochrome DiOC6 following measurement of v8m by
£ow cytometric analysis (Fig. 6). Cells incubated with querce-
tin for 4.5 h showed a striking reduction in v8m (Fig. 6A),
more evident than that observed in cells incubated with anti-
CD95 (Fig. 6C), and comparable to that detectable in cells
incubated with quercetin and anti-CD95 together (Fig. 6B).
Therefore, it appears that HPB-ALL, as opposed to other cell
lines, is not sensitive to changes in v8m induced by anti-
CD95. On the contrary, the pro-apoptotic activity of querce-
tin might be mediated by the apoptotic pathway(s) correlated
to reduction in v8m.
3.7. Antioxidative e¡ect of quercetin in HPB-ALL cells
Several observations suggest that reactive oxygen species
(ROS) may mediate programmed cell death, although it is
not clear how essential they are in generating apoptosis [37].
On the other hand, a role of antioxidants in enhancing apop-
tosis has been reported [38,39]. In addition, it has been dem-
onstrated that an increase in superoxide anions blocks apop-
tosis triggered by CD95 in melanoma cells [40]. Therefore, we
veri¢ed whether or not quercetin lowers ROS in our system.
Fig. 7 shows that quercetin at a concentration of 50 WM was
able to block ROS production in HPB-ALL cells, indicating
that the molecule keeps its antioxidant property in the system
we tested. The decrease in ROS production was detectable
after 5 min of quercetin application to cells. We also demon-
strated that: (i) ROS levels did not change in the presence of
anti-CD95 antibody (data not reported); (ii) when quercetin
and anti-CD95 were added together, ROS decreased with the
same kinetic as shown in Fig. 7 (data not reported).
4. Discussion
In this report we have presented data on the pro-apoptotic
e¡ects of a naturally occurring £avonoid, quercetin, in a ma-
lignant cell line tested, namely HPB-ALL. We demonstrated
that quercetin per se does not induce apoptosis. However, the
molecule in association with anti-CD95 monoclonal antibody,
active in inducing apoptosis in cells expressing CD95 receptor,
strongly increases apoptosis. To our knowledge, this is the
¢rst time that the supposed pro-apoptotic activity of quercetin
is linked to the CD95 pathway of apoptosis induction.
The concentration of quercetin used in this study is not far
from that present in Mediterranean diet [6]. In rats, plasma
concentration of quercetin reaches a value of 115 WM after an
oral administration of 1 g/die [41], while in humans the plas-
ma concentration of quercetin after a meal rich in £avonoids
is in the micromolar range [42] to indicate a high uptake of
the molecule. Finally, resveratrol, a well known cancer che-
mopreventive agent [43], is present in food at a concentration
10-fold lower than quercetin [7].
Quercetin is cytotoxic in HPB-ALL, where it causes mortal-
ity without arrest within 24 h. When we examined the rapid
induction of apoptosis in HPB-ALL cells, we observed a pos-
itive e¡ect of quercetin in enhancing CD95-induced apoptosis.
It is worthwhile to note that the cell line considered in our
study was resistant to CD95, and quercetin was able to bypass
this resistance. Therefore, we will discuss possible mechanisms
explaining quercetin activity.
A signi¢cant number of evidence correlates the antioxidant
property of several molecules with their ability to induce
apoptosis. N-acetyl-L-cysteine lowers ROS production and in-
hibits the mitogenic activity of cells expressing H-RasV12
[39,44]. Similarly, the antioxidants PDTC (pyrrolidinedithio-
carbamate) and vitamin E induce apoptosis in colorectal can-
cer cell lines [38]. Finally, CD95-mediated apoptosis is inhib-
ited by increasing concentration of superoxide anion [40].
Therefore, we might hypothesize that quercetin increased
apoptosis in our systems simply acting as antioxidant and
lowering the level of ROS (Fig. 7). However, our preliminary
data showed that this is not the case. In fact, di¡erent £avo-
noids, structurally similar to quercetin, are able to lower ROS
production in HPB-ALL as reported for quercetin (Fig. 7),
but the same molecules do not induce apoptosis in association
with anti-CD95 (M. Russo and G.L. Russo, in preparation).
In addition, the controversial theory that cell death is often
associated with a strong production of ROS [45] has not been
veri¢ed in our cells, according to our hypothesis that ROS are
not involved in quercetin action. In fact, HPB-ALL cells
treated with anti-CD95 do not show any variation of ROS
levels (data not reported). Our results are in agreement with
others suggesting that ROS production might be a conse-
quence and not the cause of apoptosis [37,46], but di¡er
from those reporting that ROS production is associated
with anti-CD95 treatment [47]. Presently, we cannot exclude
Fig. 7. E¡ect of quercetin on intracellular ROS. HPB-ALL cells
(1U106) were treated with 10 WM DCFDA and incubated with 50
WM quercetin at di¡erent times. ROS production was monitored as
DCF £uorescence as reported in Section 2. Each time point repre-
sents the average of two di¡erent experiments in duplicate þ stan-
dard error.
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that quercetin might modify key functional residues on pro-
teins (e.g. sulphydryl groups) and thereby alter their function.
Several examples of these mechanisms are reported in litera-
ture, e.g. [37].
The apoptotic signaling initiated by CD95 is transmitted to
caspase-3 throughout two main pathways: the DISC/caspase-
8 [26], and the mitochondria/cytochrome C/Apaf-1/caspase-9
pathways [27]. Mitochondria play an important role in cell
death signaling [48] : alterations in mitochondrial structure
and function occur in early stages of apoptosis [49]. In several
systems, activation of CD95 to its receptors leads to alteration
in mitochondrial membrane with the consequent release of
cytochrome C that binds to Apaf-1 triggering apoptosis
[48,50]. In addition, Sca⁄di et al. [27] reported that in relation
to the cell type two di¡erent pathways of CD95-mediated
apoptosis can be identi¢ed: type I cells involve strong casp-
ase-8 activation bypassing mitochondria, while type II cells
hold an essential role due to the loss of mitochondria func-
tion. We believe that HPB-ALL cells belong to type I for the
following reasons: (i) Fig. 6 of this report shows that anti-
CD95 does not induce any variation in v8m ; (ii) immunoblot-
ting of anti-CD95 treated HPB-ALL cells indicated that the
level of Bcl-2 expression does not change (M. Russo and G.L.
Russo, in preparation), while mitochondrial-induced apopto-
sis is blocked by overexpression of bcl-2 [27] and down-regu-
lation of bcl-2 is associated with CD95-mediated apoptosis in
several systems [51]; therefore, it is plausible that mitochon-
dria are not involved. Concerning the mechanism explaining
quercetin activity, it clearly involves the loss of mitochondrial
function (Fig. 6); thus, it is reasonable that induction of cy-
tochrome C by quercetin activates the apoptotic Apaf-1/casp-
ase-9 pathway increasing the answer to anti-CD95 observed
in our cells. It remains to be demonstrated whether quercetin
triggers v8m directly or throughout the generation of another
intermediate able to modify mitochondrial membrane poten-
tial. Accordingly, a recent work reports that quercetin is able
to inhibit mitochondrial membrane permeability transition
[52]. An apparent contradiction of our model is that quercetin
by itself does not induce apoptosis. The puzzle can be solved
by hypothesizing that the amount of cytochrome C released
by quercetin is not su⁄cient to activate caspases, but remains
docked by its high-a⁄nity binding sites to electron transport
chain until CD95 pathway is activated [48].
Unlike normal cells, many cancer cells are relatively resist-
ant to CD95-mediated apoptosis. This advantage could be
fundamental to tumor progression. Di¡erent mechanisms
have been described to explain how alterations of the CD95
system could result in the escape of tumor cells from immu-
nosurveillance [53]. Among cancer types relatively resistant to
CD95-mediated cell death, are included: colon cancer and T-
ALL from which the cell line used in the present study is
derived [25]. One way to recover CD95 sensitivity is to employ
chemotherapeutic agents such as quercetin that might enhance
apoptosis in cancer cells by activating alternative pro-apop-
totic pathways parallel to CD95 (as possibly in our case), or
independent from it. In this respect, quercetin is currently in
use in phase I clinical trials at doses not exceedingly di¡erent
from the concentration generally used in the in vitro study
and with low toxicity [54].
Considering the abundance of quercetin in Mediterranean
diet, a better knowledge of its antineoplastic and pro-apop-
totic properties could support its potential use as chemopre-
ventive agent.
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